Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
About this study
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.
- Condition
- Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
- Sponsor
- Washington University School of Medicine
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Accepted
Inclusion 3
- Minimum age: 18 years
- Study condition: Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
- Eligible healthy donors will be at least 18 years of age.
Exclusion 1
- Healthy donors younger than 18 years of age
Where
1 site, 1 recruiting
Washington University School of Medicine
St Louis, Missouri, United States
Contact
-
Melissa Reimers, M.D.
314-362-7249 cbumb@wustl.edu
Potential match only. Final eligibility is determined by the study team.